Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells

Journal of Immunology

Volumn 171, Issue 7, 2003, Pages 3863-3871

  Bharti, Alok C ^a   Donato, Nicholas ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; DEXAMETHASONE; INTERLEUKIN 6; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0141955061     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.7.3863     Document Type: Article

References (73)

1. Hallek, M., P. L. Bergsagel, and K. C. Anderson. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3.
2. UK myeloma forum. British Committee for Standards in Haemotology. 2001. Diagnosis and management of multiple myeloma. Br. J. Haematol. 115:522.
3. Anonymous. 1992. Report. In 1973-1989 Annual Cancer Statistics Review. National Cancer Institute, Bethesda.
4. Feinman, R., J. Koury, M. Thames, B. Barlogie, J. Epstein, and D. S. Siegel. 1999. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93:3044.
5. Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, et al. 1988. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83.
6. Klein, B., X. G. Zhang, Z. Y. Lu, and R. Bataille. 1995. Interleukin-6 in human multiple myeloma. Blood 85:863.
7. Darnell, J. E., Jr. 1997. STATs and gene regulation. Science 277:1630.
8. Taga, T., and T. Kishimoto. 1997. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:797.
9. Bromberg, J. F., C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell Biol. 18:2553.
10. Turkson, J., T. Bowman, R. Garcia, E. Caldenhoven, R. P. De Groot, and R. Jove. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. 18:2545.
11. Garcia, R., and R. Jove. 1998. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5:79.
12. Garcia, R., C. L. Yu, A. Hudnall, R. Catlett, K. L. Nelson, T. Smithgall, D. J. Fujita, S. P. Ethier, and R. Jove. 1997. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 8:1267.
13. Weber-Nordt, R. M., C. Egen, J. Wehinger, W. Ludwig, V. Gouilleux-Gruart, R. Mertelsmann, and J. Finke. 1996. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809.
14. Takemoto, S., J. C. Mulloy, A. Cereseto, T. S. Migone, B. K. Patel, M. Matsuoka, K. Yamaguchi, K. Takatsuki, S. Kamihira, J. D. White, et al. 1997. Proliferation of adult T cell leukemiaflymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. USA 94:13897.
15. Catlett-Falcone, R., T. H. Landowski, M. M. Oshiro, J. Turkson, A. Levitzki, R. Savino. G. Ciliberto, L. Moscinski, J. L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105.
16. Tu, Y., S. Renner, F. Xu, A. Fleishman, J. Taylor, J. Weisz, R. Vescio, M. Rettig, J. Berenson, S. Krajewski, et al. 1998. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 58:256.
17. L: a little bit of this and a little bit of STAT. Curr. Opin. Oncol. 12:543.
18. Pettersson, M. H. Jernberg-Wiklund, L. G. Larsson, C. Sundstrom, I. Givol, Y. Tsujimoto, and K. Nilsson. 1992. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79:495.
19. Tu, Y., F. H. Xu, J. Liu, R. Vescio, J. Berenson, C. Fady, and A. Lichtenstein. 1996. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88:1805.
20. Bharti, A. C., N. Donato, S. Singh, and B. B. Aggarwal. 2003. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053.
21. L, NF-κB, and p53. Clin. Immunol. 93:152.
22. Mukhopadhyay, A., S. Banerjee, L. J. Stafford, X. Xia Chunzhi, M. Liu, and B. B. Aggarwal. Circumin-induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21:8852.
23. Fujio, Y., K. Kunisada. H. Hirota, K. Yamauchi-Takihara, and T. Kishimoto. 1997. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J. Clin. Invest. 99:2898.
24. WA1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19:5419.
25. Nilsson, K., H. Bennich, S. G. Johansson, and J. Ponten. 1970. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7:477.
26. Goldman-Leikin, R. E., H. R. Salwen, C. V. Herst, D. Variakojis, M. L. Bian, M. M. Le Beau, P. Selvanayagan, R. Marder, R. Anderson, S. Weitzman, et al. 1989. Characterization of a novel myeloma cell line, MM.1. J. Lab. Clin. Med. 113:335.
27. Moalli, P. A., S. Pillay, D. Weiner, R. Leikin, and S. T. Rosen. 1992. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 79:213.
28. Manna, S. K., H. J. Zhang, T, Yan, L. W. Oberley, and B. B. Aggarwal. 1998. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-κB and activated protein-1. J. Biol. Chem. 273:13245.
29. Meydan, N., T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J. S. Leeder, M. Freedman, A. Cohen, A. Gazit. et al. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645.
30. Turkson, J., D. Ryan, J. S. Kim, Y. Zhang, Z. Chen. E. Haura, A. Laudano, S. Sebti, A. D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276:45443.
31. Schwab, G., C. B. Siegall, L. A. Aarden, L. M. Neckers, and R. P. Nordan. 1991. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 77:587.
32. Borset, M., A. Waage, O. L. Brekke, and E. Helseth. 1994. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur. J. Haematol. 53:31.
33. Hata, H., H. Matsuzaki, and K. Takatsuki. 1990. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor α, in the myeloma cell line KHM-IA. Acta Haematol. 83:133.
34. Bataille, R., B. Klein, M. Jourdan, J. F. Rossi, and B. G. Durie. 1989. Spontaneous secretion of tumor necrosis factor-β by human myeloma cell lines. Cancer 63:877.
35. Garrett, I. R., B. G. Durie, G. E. Nedwin, A. Gillespie, T. Bringman, M. Sabatini, D. R. Bertolini, and G. R. Mundy. 1987. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 317:526.
36. Miscia, S., M. Marchisio, A. Grilli, V. Di Valerio, L. Centurione, G. Sabatino, F. Garaci, G. Zauli, E. Bonvini, and A. Di Baldassarre. 2002. Tumor necrosis factor α (TNF-α) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. Cell Growth Differ. 13:13.
37. Guo, D., J. D. Dunbar, C. H. Yang, L. M. Pfeffer, and D. B. Donner. 1998. Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J. Immunol. 160:2742.
38. Keller, E. T., and W. B. Ershler. 1995. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J. Immunol. 154:4091.
39. Natarajan, C., and J. J. Bright. 2002. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 168:6506.
40. Li, W. Q., F. Dehnade, and M. Zafarullah. 2001. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J. Immunol. 166: 3491.
41. Kopantzev, Y., M. Heller, N. Swaminathan, and S. Rudikoff. 2002. IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells. Oncogene 21:6791.
42. Schreiner, S. J., A. P. Schiavone, and T. E. Smithgall. 2002. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J. Biol. Chem. 277:45680.
43. Ren, Z., and T. S. Schaefer. 2002. ErbB-2 activates Stat3 α in a Src- and JAK2-dependent manner. J. Biol. Chem. 277:38486.
44. Zamo, A., R. Chiarle, R. Piva, J. Howes, Y. Fan, M. Chilosi, D. E. Levy, and G. Inghirami. 2002. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21:1038.
45. Garcia, R., T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C. E. Cox, R. Falcone, R. Fairclough, S. Parsons, et al. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499.
46. Zhang, Y., J. Turkson, C. Carter-Su, T. Smithgall, A. Levitzki, A. Kraker, J. J. Krolewski, P. Medveczky, and R. Jove. 2000. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem. 275:24935.
47. Zong, C. S., J. Chan, D. E. Levy, C. Horvath, H. B. Sadowski, and L. H. Wang. 2000. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 275:15099.
48. Wang, Y. Z., W. Wharton, R. Garcia, A. Kraker, R. Jove, and W. J. Pledger. 2000. Activation of Stat3 preassembled with platelet-derived growth factor β receptors requires Src kinase activity. Oncogene 19:2075.
49. Jain, N., T. Zhang, W. H. Kee, W. Li, and X. Cao. 1999. Protein kinase Cδ associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J. Biol. Chem. 274:24392.
50. Sellers, L. A., W. Feniuk, P. P. Humphrey, and H. Lauder. 1999. Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase: resultant effects on cell proliferation. J. Biol. Chem. 274:16423.
51. Liu, J. J., K. Nakajima, T. Hirano, and H. F. Yang-Yen. 1998. Activation of Stat3 by v-Src is through a Ras-independent pathway. J. Biomed. Sci. 5:446.
52. Park, W. Y., J. H. Ahn, R. A. Feldman, and J. S. Seo. 1998. c-Fes tyrosine kinase binds to and activates STAT3 after granulocyte-macrophage colony-stimulating factor stimulation. Cancer Lett. 129:29.
53. Chaturvedi, P., M. V. Reddy, and E. P. Reddy. 1998. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 16:1749.
54. Park, O. K., T. S. Schaefer, and D. Nathans. 1996. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc. Natl. Acad. Sci. USA 93:13704.
55. Nelson, K. L., J. A. Rogers, T. L. Bowman, R. Jove, and T. E. Smithgall. 1998. Activation of STAT3 by the c-Fes protein-tyrosine kinase. J. Biol. Chem. 273:7072.
56. De Vos, J., M. Jourdan, K. Tarte, C. Jasmin, and B. Klein. 2000. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br. J. Haematol. 109:823.
57. Reddy, S., and B. B. Aggarwal. 1994. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett. 341:19.
58. neu. Clin. Cancer Res. 5:1884.
59. Korutla, L., and R. Kumar. 1994. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta 1224:597.
60. Yu, C. L., D. J. Meyer, G. S. Campbell, A. C. Larner, C. Carter-Su, J. Schwartz, and R. Jove. 1995. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81.
61. Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19:2474.
62. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell. Jr. 1999. Stat3 as an oncogene. Cell 98:295.
63. Takeda, K., T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto, and S. Akira. 1998. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161:4652.
64. Shen, Y., G. Devgan, J. E. Darnell, Jr., and J. F. Bromberg. 2001. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. USA 98:1543.
65. Song, J. I., and J. R. Grandis. 2000. STAT signaling in head and neck cancer. Oncogene 19:2489.
66. Yoshikawa, H., K. Matsubara, G. S. Qian, P. Jackson, J. D. Groopman, J. E. Manning, C. C. Harris, and J. G. Herman. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:29.
67. Zhang, Q., P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik. 2002. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 168:466.
68. Galm, O., H. Yoshikawa, M. Esteller, R. Osieka, and J. G. Herman. 2003. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784.
69. Lal, B., A. K. Kapoor, P. K. Agrawal, O. P. Asthana, and R. C. Srimal. 2000. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother. Res. 14:443.
70. Lal, B., A. K. Kapoor, O. P. Asthana, P. K. Agrawal, R. Prasad, P. Kumar, and R. C. Srimal. 1999. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother. Res. 13:318.
71. Plummer, S. M., K. A. Hill, M. F. Festing, W. P. Steward, A. J. Gescher, and R. A. Sharma. 2001. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol. Biomarkers Prev. 10:1295.
72. Cheng, A. L., C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J, Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk of pre-malignant lesions. Anticancer Res. 21:2895.
73. Sharma. R. A., H. R. McLelland, K, A. Hill, C. R. Ireson, S. A. Euden, M. M. Manson, M. Pirmohamed, L. J. Marnett, A, J. Gescher, and W. P. Steward. 2001. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7:1894.